Xtreme Touch Neo – Only sirolimus coated PTA balloon cathether

Concept Medical has developed a SIROLIMUS coated peripheral balloon catheter for unique indications.

Surat, India: Concept Medical known for being an innovative company has added one more unique product to its portfolio, a Sirolimus coated peripheral balloon catheter, Xtreme Touch Neo. The balloon has been introduced because of the current limitations of Paclitaxel coated balloons available in the market.

About Xtreme Touch Neo

Xtreme Touch Neo has been developed with Nanolute Technology which is a nano carrier based drug elution technology. The encapsulation technology uses biocompatible excipients where the nano particle drug in encapsulated in nano particle drug carrier. This helps the particle to penetrate in the innermost layer of the vessel wall with the reduction of the particle size.
Xtreme Touch Neo is designed by limiting drug dose, coating stability, maximise drug tissue transfer and maintaining drug efficacy over time. The lower loading dose by reducing the particulate matter, uniform coating in the inflated position, maximising drug tissue transfer through nano carrier and maintain drug efficacy over time by drug nano particle ensures encouraging results. Xtreme Touch Neo is indicated for Iliac artery, Superficial Femoral Artery, Below the Knee. It is also being applied to treat complex indications like Arteriovenous Fistula, Arteriovenous Graft. The company is awaiting for CE approval of Xtreme Touch Neo from European Competent Authority and is expected to arrive in 2018.

About MagicTouch

MagicTouch is a sirolimus coated balloon catheter for percutaneous transluminal coronary application intended for in-stent restenosis, small vessels and bifurcation lesions.
A very viable alternative in situations where metallic stent is not a first option” explained Dr. Alexandre Abizaid, MD, Ph.D., FACC.


Eastbourne is a European Prospective, spontaneous, multicentre registry on MagicTouch (sirolimus drug coated balloon catheter) aiming to observe and evaluate the performance of a Sirolimus-eluting Drug-Coated Balloon (SCB) for the treatment of any type of coronary lesions, including native vessel disease and in-stent restenosis. The study is led by Dr. Bernardo Cortese (A.O. Fatebenefratelli, Milano). Primary endpoint is Target Lesion Revascularization at 12 months. Secondary endpoints of the study include: MACE (Major Adverse Cardiac Events) as a composite of cardiac death, myocardial infarction (MI) and TLR at 6, 12 and 24 months; any individual element of MACE; procedural success (defined as technical and angiographic success in the absence of MACE during hospitalization). The registry is ongoing with more than 340 patients enrolled in various European countries.

About Concept Medical

Concept Medical is India based research division of CMI founded in 2008, which is dedicated for research and development of drug delivering medical devices in various medicinal application including cardiovascular and peripheral medical devices. The company is currently developing novel drug for oncology application.



Source: Concept Medical